SCHEMBL26088078

SCHEMBL26088078

CC1CCc2c1cc(C(=O)Nc1ccc(F)cn1)c(=O)n2C

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 6/20 0.66
▸ JAK2 O60674 1/20 0.44
▸ NTRK1 P04629 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ GRM5 P41594 4/20 0.41
▸ F10 P00742 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ HTR1F P30939 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26419319 1.00 AHR (0.66) AHRJAK2NTRK1KDM4EMEN1
SCHEMBL26419324 1.00 AHR (0.66) AHRJAK2NTRK1KDM4EMEN1
SCHEMBL30345457 1.00 AHR (0.66) AHRJAK2NTRK1KDM4EMEN1
SCHEMBL26419325 0.87 AHR (0.60) AHRF10
SCHEMBL26086682 0.87 AHR (0.60) AHRF10
SCHEMBL26419331 0.87 AHR (0.60) AHRF10
SCHEMBL26089047 0.86 AHR (0.70) AHRJAK2NTRK1MAPTHTR1F
SCHEMBL26087025 0.86 AHR (0.70) AHRJAK2NTRK1MAPTHTR1F
SCHEMBL26086751 0.86 AHR (0.70) AHRJAK2NTRK1MAPTHTR1F
SCHEMBL26086628 0.83 AHR (0.63) AHRKDM4EMEN1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037322-B2 AHR agonists AHR, ARNT, RORC AHR 1/4885JAK2 646/4885NTRK1 1283/4885
US-20230127797-A1 AHR AGONISTS AHR, ARNT, RORC AHR 1/4885JAK2 646/4885NTRK1 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback